Wockhardt share news, announcements and annual reports
NSE: WOCKPHARMABSE: 532300Pharmaceuticals & BiotechnologySmall Cap
Wockhardt Limited · Face value ₹5 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Feb 2000
Last close ₹1,896.50down ₹4.60 (0.24%)BSE ₹1,892.15
Share price at the NSE close on 2 Nov 2026. Previous close ₹1,901.10.
2 Nov: open ₹1,903.10, high ₹1,915.00, low ₹1,864.10
52-week range of traded prices to 2 Nov 2026
₹1,086.70Low, 23 Mar 2026₹2,422.30High, 1 Jun 2026
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹30,817 Cr311th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 75.16
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 5.97
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 8.4%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 7.0%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Sep 2026.
- 0.39
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 6,06,59351.5% delivered
Wockhardt share news and announcements
1,014 announcements, routine notices left out, newest first. Page 19 of 21.
Jun 2009
1 Jun · Limited Review Report
Auditors have conducted the limited review for the un-audited financial results for the quarter ended March 31, 2009. The Limited Review Report and reasons for vaiation have been approved by the Board of Directors at their meeting held on May 29, 2009. The details of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
May 2009
29 May · Business
Press release dated May 29, 2009, titled "Wockhardt appoints BDO Haribhakti as auditor". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.5 May · Meeting
Annual General Meeting of the members of the Company will be held on June 29, 2009. Further, the register of members and share transfer books shall remain closed from June 23, 2009 to June 29, 2009 (both days inclusive) for the purpose of Annual General Meeting.5 May · Meeting
Pursuant to Section 192A of the Companies Act, 1956, read with the Rule 4(f) of the Companies (Passing of the Resolution by Postal Ballot) Rules, 2001, the approval of the shareholders has to be obtained by passing shareholders' resolution through Postal Ballot: Ordinary Resolution under Section 293 (1) (a) of the Companies Act, 1956 for transfer, sell and/or dispose off of the Animal Healthcare Business of the Company. The Company has appointed Mr. Virendra Bhatt, Practicing Company Secretary, as Scrutinizer for conducting the Postal Ballot process in a fair and transparent manner. The duly completed postal ballot form should reach the Company before the close of working hours on June 01, 2009. The results of postal ballot will be announced by the Chairman on June 02, 2009. The Notice of Postal Ballot shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Apr 2009
29 Apr · Business
Press release dated April 29, 2009, titled "Wockhardt announces Entacapone patent settlement with Orion Corporation". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.24 Apr · Results
Consolidated Results for the quarter ended on 31-DEC-2008 as follows: Net Sales of Rs. 95190 lacs for quarter ending on 31-DEC-2008 against Rs. 76200 lacs for the quarter ending on 31-DEC-2007. Net Profit / (Loss) of Rs. (35784) lacs for the quarter ending on 31-DEC-2008 against Rs. 10690 lacs for the quarter ending on 31-DEC-2007.24 Apr · Board meeting
Board of Directors at their meeting held on April 24, 2009 transacted the following business : (1) Approval of the notice of postal ballot along with the postal ballot form and calendar of events for obtaining consent of the members of the Company for sale / transfer / disposal of Animal Healthcare Business of the Company to its subsidiary/ any other entity /parties as may be decided by the Board as a going concern or otherwise at such price and on such terms and conditions as may be decided by the board.24 Apr · Business
Press release dated April 24, 2009, titled "Consolidated sales grew by 35.4% to Rs. 3,593 crores Operating Profits (EBITDA) grew by 26.5% to Rs. 808 crores". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.24 Apr · Results
Consolidated Results for the year ended on 31-DEC-2008 as follows: Net Sales of Rs. 359256 lacs for year ending on 31-DEC-2008 against Rs. 265320 lacs for the year ending on 31-DEC-2007. Net Profit / (Loss) of Rs. (13886) lacs for the year ending on 31-DEC-2008 against Rs. 38580 lacs for the year ending on 31-DEC-2007.24 Apr · Results
Consolidated Results for the quarter ended on 31-MAR-2009 as follows: Net Sales of Rs. 86940 lacs for quarter ending on 31-MAR-2009 against Rs. 78570 lacs for the quarter ending on 31-MAR-2008. Net Profit / (Loss) of Rs. (2024) lacs for the quarter ending on 31-MAR-2009 against Rs. 5090 lacs for the quarter ending on 31-MAR-2008.24 Apr · Results
Standalone Results for the quarter ended on 31-DEC-2008 as follows: Net Sales of Rs. 37371 lacs for quarter ending on 31-DEC-2008 against Rs. 29540 lacs for the quarter ending on 31-DEC-2007. Net Profit / (Loss) of Rs. (38632) lacs for the quarter ending on 31-DEC-2008 against Rs. 3390 lacs for the quarter ending on 31-DEC-2007.24 Apr · Results
Standalone Results for the year ended on 31-DEC-2008 as follows: Net Sales of Rs. 150389 lacs for year ending on 31-DEC-2008 against Rs. 123680 lacs for the year ending on 31-DEC-2007. Net Profit / (Loss) of Rs. (34875) lacs for the year ending on 31-DEC-2008 against Rs. 21390 lacs for the year ending on 31-DEC-2007.24 Apr · Results
Standalone Results for the quarter ended on 31-MAR-2009 as follows: Net Sales of Rs. 35359 lacs for quarter ending on 31-MAR-2009 against Rs. 32970 lacs for the quarter ending on 31-MAR-2008. Net Profit / (Loss) of Rs. (3044) lacs for the quarter ending on 31-MAR-2009 against Rs. 70 lacs for the quarter ending on 31-MAR-2008.15 Apr · Board meeting
Interalia to transact the following business:-(1) To consider and approve the audited Financial Accounts of the Company for the year ended December 31, 2008. (2) To consider and approve the audited Financial Results of the Company for the quarter and year ended December 31, 2008. (3) To consider and approve unaudited financial results of the Company for the quarter ended March 31, 2009.1 Apr · Business
Press release dated April 01, 2009, titled "Wockhardt announces its succession plan under the leadership of Chairman Habil Khorakiwala: Dr. Murtaza Khorakiwala is Managing Director, Huzaifa Khorakiwala is Executive Director". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Mar 2009
31 Mar · Board meeting
On account of a potential restructuring of certain businesses of the Company and its subsidiaries which the Company is currently evaluating, the statutory audit of the accounts of the Company could not be completed as scheduled. The company expect that the audit of the annual accounts of the Company for the financial year ended December 31, 2008 would be completed by April 25, 2009 and will be published forthwith upon such completion. Further, at the Board Meeting held on March 31, 2009 the following business was transacted amongst others:(1). Mr. H F Khorakiwala, who is presently Chairman & Managing Director will continue as Executive Chairman on the Board and resign from the post of Managing Director.(2). The Board appointed Dr. Murtaza H. Khorakiwala as Additional Director and subject to the approval of members in general meeting, as Managing Director of the Company w.e.f. March 31, 2009.(3). The Board appointed Mr. Huzaifa H. Khorakiwala as Additional Director and subject to the approval of members in general meeting as Whole- time Director designated as Executive Director of the Company w.e.f. March 31, 2009.(4). In view of the adverse market conditions, liquidity constraints and debt burden, the Board decided to make a reference to Corporate Debt Restructuring Cell (CDR Cell) through ICICI Bank Limited, for financial restructuring of the debts of the Company, through Corporate Debt Restructuring Mechanism. The details of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.20 Mar · Board meeting
Interalia to transact the following business:-(1) To consider and approve the Audited Financial Accounts of the Company for the year ended December 31, 2008. (2) To consider and approve the Audited Financial Results of the Company for the quarter and year ended December 31, 2008. (3) To consider dividend, if any, to be recommended on equity shares for the year ended December 31, 2008.2 Mar · Demise of Director
Dr. B.L. Maheshwari, Non-Executive and Independent Director of the Company passed away on March 01, 2009. The Board places on record its appreciation for the valuable guidance and contribution to the Board made by him during his tenure as a Director of the Company and extends its deepest condolence to his family.
Feb 2009
26 Feb · Business
Press release dated February 26, 2009, titled "Wockhardt to launch generic version of ulcer drug Ranitidine syrup in the US market". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.17 Feb · Business
Press release dated February 17, 2009, titled "Wockhardt to launch generic version of migraine drug Sumatriptan in the US market". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.12 Feb · Business
Press release dated February 12, 2009, titled "Wockhardt to launch Leveiracetam, a generic version of epilepsy drug in the US market". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.11 Feb · Business
Press release dated February 11, 2009, titled "Wockhardt to launch Divalproex ER in the US market; Gets US FDA approval for generic version of epilepsy drug". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.10 Feb · Business
Press release dated February 10, 2009 titled "A biotechnology breakthrough in Diabetes; Wockhardt launches new insulin (Glaritus) in India; First in the world after innovator". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.10 Feb · Disclosure
Disclosure under Regulation 8A(4) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 1997, giving details of shares pledged by promoters. The copy of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.3 Feb · Updates
Copies of the Annual Disclosures of securities holdings received by the Company from its Directors/Officers for the year ended December 31, 2008. The details of the list of Annual Disclosures of Securities held by the Directors & Officers shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Jan 2009
27 Jan · Updates
Copies of the Annual Disclosures of securities holdings received by the Company from its Directors/Officers for the year ended December 31, 2008. The details of the list of Annual Disclosures of Securities held by the Directors & Officers shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.19 Jan · Meeting
An Extraordinary General Meeting of the members of the Company was duly held on January 19, 2009 and the following resolutions were passed unanimously at the meeting by the members of the Company: (1) Increase in Authorised Share Capital from Rs. 125 Crores to Rs. 175 Crores by creation of 10 Crore preference shares of Face Value of Rs. 5/- each & consequential amendments in Memorandum and Articles of Association of the Company. (2) Issue of Redeemable Preference Shares of Face Value of Rs. 5/- each at such price as may be decided by the Board in its absolute discretion such that aggregate amount raised through the issue does not exceed Rs. 500 Crores.14 Jan · Business
Press release dated January 14, 2009, titled "Wockhardt signs in-licensing agreement with a Swiss firm for Bonistein; In-licensing deal to market Bonistein, a patented product, specially designed for Osteoporosis". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.6 Jan · Results
Company will submit Audited Financial Results for the entire Financial Year ended December 31, 2008 on or before March 31, 2009 and hence the unaudited financial results for the last quarter ended December 31, 2008 will not be submitted to the Exchange.
Dec 2008
26 Dec · Meeting
Notice of the Extra-Ordinary General Meeting scheduled to be held on January 19, 2009. A copy of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.19 Dec · News Verification
News Verification : The media had reports that Wockhardt Limited may sell its french arm Negma Lab and Irish subsidiary Pinewood. The Exchange, in order to verify the accuracy or otherwise of the information reported in the media and to inform the market place so that the interest of the investors is safeguarded, had written to the officials of the company. Wockhardt Limited has vide its letter inter-alia stated,"Appropriate disclosures to the exchanges will be made in case the Company plans to divest the subsidiaries and enters into definitive agreement."19 Dec · Increase in authorised share capital/others
Board has decided to convene an Extraordinary General Meeting of the members of the Company on January 19, 2009 to consider and approve the following matters: (1) Issue of Redeemable Preference Shares of Face Value of Rs. 5/- each upto Rs. 500 Crores. (2) Increase in Authorized Share Capital from Rs. 125 Crores to Rs. 175 Crores by creation of 10 Crore preference shares of Face Value of Rs. 5/- each & consequential amendments in Memorandum and Articles of Association of the Company.4 Dec · Business
Press release dated December 04, 2008, titled "Wockhardt receives US FDA approval for generic version of Augmentin* Suspension". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.2 Dec · Limited Review Report
Auditor's have conducted the limited review of the un-audited financial results for the quarter ended September 30, 2008. The details of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Nov 2008
14 Nov · Business
Press release dated November 13, 2008, titled "Wockhardt Launches Midazolam in the US Market, Gets US FDA approval for generic version of insomnia drug". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Oct 2008
21 Oct · Management
Mr. Vijay R. Khetan is appointed as Compliance Officer of the Company in place of Mr. Rajiv B. Gandhi21 Oct · Results
Standalone Results for the quarter ended on 30-SEP-2008 as follows: Net Sales of Rs. 41683 lacs for quarter ending on 30-SEP-2008 against Rs. 34490 lacs for the quarter ending on 30-SEP-2007. Net Profit / (Loss) of Rs. 1343 lacs for the quarter ending on 30-SEP-2008 against Rs. 5890 lacs for the quarter ending on 30-SEP-2007.21 Oct · Results
Consolidated Results for the quarter ended on 30-SEP-2008 as follows: Net Sales of Rs. 92348 lacs for quarter ending on 30-SEP-2008 against Rs. 73810 lacs for the quarter ending on 30-SEP-2007. Net Profit / (Loss) of Rs. 6219 lacs for the quarter ending on 30-SEP-2008 against Rs. 10830 lacs for the quarter ending on 30-SEP-2007.16 Oct · Business
Press release dated October 16, 2008, titled "Wockhardt gets US FDA nod to market Ceftazidime injections". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.10 Oct · Business
Press release dated October 08, 2008, titled "Wockhardt takes huge strides towards In-licensing and collaborative agreements - Signs in-licensing deal with UK based Sinclair Pharma". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.8 Oct · Board meeting
Inter alia, to consider and approve the unaudited financial results of the Company for the quarter and nine months ended September 30, 2008.
Aug 2008
13 Aug · Limited Review Report
Auditor's have conducted the limited review of the Unaudited financial results for the quarter ended June 30, 2008 and found the same to be in order subject to certain observations. The auditor's observations are: Without qualifying our opinion, we state that the unaudited financial results are without provision for premium payable on 108,500 Zero Coupon Foreign Currency Convertible Bonds of USD 1000 each as the premium payable on redemption is presently not determinable, which is contingent upon a future uncertain event, namely, the redemption of such bonds. The charge for premium outstanding FCCB for the quarter works out to Rs.134.38 million.(Rs. 25.02 millions for the quarter ended June 30, 2007) and cumulative liability as at the quarter end amounts to a maximum of Rs. 992.60 millions (Rs. 666.99 millions as at the quarter ended June 30, 2007).
Jul 2008
29 Jul · Updates
Vide notes to Accounts in the Unaudited Financial Results for the quarter ended June 30, 2008 (taken on record by the Board of the directors of the Company at its meeting held on July 28, 2008) that pursuant to the announcement on "Accounting for Derivatives" issued by the Institute of Chartered Accountants of India in March 2008, the Company has accounted Mark-to-Market (MTM) losses aggregating Rs.2,789 lakhs during the quarter ended March 2008, which have reduced by Rs. 1,039 lakhs during the current quarter. The Company has entered into Hedging instruments, which are long term in nature to reduce interest cost for the loans, which the Company has taken in past and is outstanding as of June 30, 2008. As per the Risk Management Policy, the Company is hedging the interest for 50% of the long term loans. The Company does not hold or issue derivative financial instruments for trading or speculative purposes. The same has been treated as an Extra-Ordinary Item".28 Jul · Results
Standalone Results for the half year ended on 30-JUN-2008 as follows: Net Sales of Rs. 71674 lacs for half year ending on 30-JUN-2008 against Rs. 59650 lacs for the half year ending on 30-JUN-2007. Net Profit / (Loss) of Rs. 2412 lacs for the half year ending on 30-JUN-2008 against Rs. 12110 lacs for the half year ending on 30-JUN-2007.28 Jul · Results
Standalone Results for the quarter ended on 30-JUN-2008 as follows: Net Sales of Rs. 38708 lacs for quarter ending on 30-JUN-2008 against Rs. 30380 lacs for the quarter ending on 30-JUN-2007. Net Profit / (Loss) of Rs. 2335 lacs for the quarter ending on 30-JUN-2008 against Rs. 6910 lacs for the quarter ending on 30-JUN-2007.28 Jul · Results
Consolidated Results for the half year ended on 30-JUN-2008 as follows: Net Sales of Rs. 172074 lacs for half year ending on 30-JUN-2008 against Rs. 115310 lacs for the half year ending on 30-JUN-2007. Net Profit / (Loss) of Rs. 15670 lacs for the half year ending on 30-JUN-2008 against Rs. 16870 lacs for the half year ending on 30-JUN-2007.28 Jul · Results
Consolidated Results for the quarter ended on 30-JUN-2008 as follows: Net Sales of Rs. 93503 lacs for quarter ending on 30-JUN-2008 against Rs. 63030 lacs for the quarter ending on 30-JUN-2007. Net Profit / (Loss) of Rs. 10587 lacs for the quarter ending on 30-JUN-2008 against Rs. 10240 lacs for the quarter ending on 30-JUN-2007.14 Jul · Board meeting
Inter alia, to consider and approve the unaudited financial results of the Company for the quarter and half year ended June 30, 2008.
Apr 2008
29 Apr · Meeting
Annual General Meeting of the Company was duly held on April 28, 2008 and the following resolutions were passed unanimously at the meeting by the members of the Company: 1) Adoption of Audited Balance Sheet as at December 31, 2007, Profit and Loss Account for the year ended on that date and the Reports of the Board of Directors and Auditors thereon. 2) Declaration of final dividend @50% on the equity shares of the Company i.e. Rs. 2.5 per share absorbing an amount of Rs. 273.59 million. 3) Re-appointment of Mr. Shekhar Datta as a Director of the Company. 4) Re-appointment of Mr. B.L. Maheshwari as a Director of the Company. 5) Appointment of M/s. S.R. Batliboi, Chartered Accountants as the Statutory Auditors of the Company to hold office till the conclusion of next Annual General Meeting of the Company.28 Apr · Results
Standalone Results for the quarter ended on 31-MAR-2008 as follows: Net Sales of Rs. 32970 lacs for quarter ending on 31-MAR-2008 against Rs. 29270 lacs for the quarter ending on 31-MAR-2007. Net Profit / (Loss) of Rs. 70 lacs for the quarter ending on 31-MAR-2008 against Rs. 5200 lacs for the quarter ending on 31-MAR-2007.